Matthew Ronsheim - May 20, 2024 Form 4 Insider Report for Innoviva, Inc. (INVA)

Role
Officer
Signature
/s/ Matthew Ronsheim
Stock symbol
INVA
Transactions as of
May 20, 2024
Transactions value $
-$4,323
Form type
4
Date filed
5/21/2024, 08:15 PM
Previous filing
Mar 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INVA Common Stock Tax liability -$4.32K -268 -0.66% $16.13 40.5K May 20, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.

Remarks:

Dr. Ronsheim is President of Innoviva Specialty Therapeutics, Inc. which is a wholly owned subsidiary of Innoviva Specialty Therapeutics Holdings, LLC, which is a wholly owned subsidiary of Innoviva, Inc.